Zobrazeno 1 - 10
of 81
pro vyhledávání: '"TAKAYOSHI MATSUDA"'
Autor:
Lusy Handoko, Bogumil Kaczkowski, Chung-Chau Hon, Marina Lizio, Masatoshi Wakamori, Takayoshi Matsuda, Takuhiro Ito, Prashanti Jeyamohan, Yuko Sato, Kensaku Sakamoto, Shigeyuki Yokoyama, Hiroshi Kimura, Aki Minoda, Takashi Umehara
Publikováno v:
Epigenetics, Vol 13, Iss 4, Pp 410-431 (2018)
The bromodomain and extra-terminal domain (BET) proteins are promising drug targets for cancer and immune diseases. However, BET inhibition effects have been studied more in the context of bromodomain-containing protein 4 (BRD4) than BRD2, and the BE
Externí odkaz:
https://doaj.org/article/a5a3e24b8e2b44a8ae4456359d3ec093
Autor:
Takayoshi Matsuda, Takuhiro Ito, Chie Takemoto, Kazushige Katsura, Mariko Ikeda, Motoaki Wakiyama, Mutsuko Kukimoto-Niino, Shigeyuki Yokoyama, Yoshikazu Kurosawa, Mikako Shirouzu
Publikováno v:
PLoS ONE, Vol 13, Iss 2, p e0193158 (2018)
Growing numbers of therapeutic antibodies offer excellent treatment strategies for many diseases. Elucidation of the interaction between a potential therapeutic antibody and its target protein by structural analysis reveals the mechanism of action an
Externí odkaz:
https://doaj.org/article/44d4887a9582438299b589d66db0bee7
Autor:
Dr. Naomi Ohbayashi, Dr. Kazutaka Murayama, Miyuki Kato‐Murayama, Dr. Mutsuko Kukimoto‐Niino, Dr. Tamami Uejima, Dr. Takayoshi Matsuda, Dr. Noboru Ohsawa, Prof. Shigeyuki Yokoyama, Prof. Hiroshi Nojima, Dr. Mikako Shirouzu
Publikováno v:
ChemistryOpen, Vol 7, Iss 9, Pp 713-719 (2018)
Abstract Gefitinib is the molecular target drug for advanced non‐small‐cell lung cancer. The primary target of gefitinib is the positive mutation of epidermal growth factor receptor, but it also inhibits cyclin G‐associated kinase (GAK). To rev
Externí odkaz:
https://doaj.org/article/1792a4ab9ff142d693f1b4b82f51f702
Autor:
Miyuki Kato-Murayama, Tamami Uejima, Naomi Ohbayashi, Hiroshi Nojima, Mutsuko Kukimoto-Niino, Shigeyuki Yokoyoma, Noboru Ohsawa, Kazutaka Murayama, Mikako Shirouzu, Takayoshi Matsuda
Publikováno v:
ChemistryOpen, Vol 7, Iss 9, Pp 713-719 (2018)
ChemistryOpen
ChemistryOpen
Gefitinib is the molecular target drug for advanced non‐small‐cell lung cancer. The primary target of gefitinib is the positive mutation of epidermal growth factor receptor, but it also inhibits cyclin G‐associated kinase (GAK). To reveal the m
Autor:
Kazushige Katsura1, Takayoshi Matsuda1, Yuri Tomabechi1, Mayumi Yonemochi1, Kazuharu Hanada1, Noboru Ohsawa1, Kensaku Sakamoto1, Chie Takemoto1 chie.takemoto@riken.jp, Mikako Shirouzu1 mikako.shirouzu@riken.jp
Publikováno v:
Journal of Biochemistry. Nov2017, Vol. 162 Issue 5, p357-369. 13p.
Autor:
Chie Takemoto, Mikako Shirouzu, Takaho Terada, Kazushige Katsura, Noboru Ohsawa, Mutsuko Kukimoto-Niino, Shigeyuki Yokoyama, Mayumi Yonemochi, Junko Mikuni, Yuri Tomabechi, Takayoshi Matsuda
Publikováno v:
Protein expression and purification. 150
Since phosphorylation is involved in various physiological events, kinases and interacting factors can be potential targets for drug discovery. For the development and improvement of inhibitors from the point of view of mechanistic enzymology, a cell
Autor:
Kensaku Sakamoto, Kazumasa Ohtake, Takayoshi Watanabe, Tatsuo Yanagisawa, Takahiro Hohsaka, Atsushi Yamaguchi, Yoshihisa Fujiwara, Takayoshi Matsuda, Shigeyuki Yokoyama
Publikováno v:
Bioconjugate Chemistry. 27:198-206
Z-Lysine (ZLys) is a lysine derivative with a benzyloxycarbonyl group linked to the ε-nitrogen. It has been genetically encoded with the UAG stop codon, using the pair of an engineered variant of pyrrolysyl-tRNA synthetase (PylRS) and tRNA(Pyl). In
Autor:
Kazushige Katsura, Takuhiro Ito, Motoaki Wakiyama, Mutsuko Kukimoto-Niino, Yoshikazu Kurosawa, Chie Takemoto, Takayoshi Matsuda, Mikako Shirouzu, Mariko Ikeda, Shigeyuki Yokoyama
Publikováno v:
PLoS ONE, Vol 13, Iss 2, p e0193158 (2018)
PLoS ONE
PLoS ONE
Growing numbers of therapeutic antibodies offer excellent treatment strategies for many diseases. Elucidation of the interaction between a potential therapeutic antibody and its target protein by structural analysis reveals the mechanism of action an
Publikováno v:
Biochemical and Biophysical Research Communications. 431:296-301
Many important therapeutic targets are secreted proteins with multiple disulfide bonds, such as antibodies, cytokines, hormones, and proteases. The preparation of these proteins for structural and functional analyses using cell-based expression syste
Autor:
Kanako Kuwasako, Shigeyuki Yokoyama, Fahu He, Naohiro Kobayashi, Takashi Yabuki, Takanori Kigawa, Takayoshi Matsuda, Eiko Seki, Yutaka Muto, Takushi Harada, Masaaki Aoki, M. Takahashi, Kengo Tsuda, Kohei Saito, Peter Güntert, Takashi Umehara, Satoru Watanabe
Publikováno v:
Structure. 18(9):1127-1139
The zinc finger CW (zf-CW) domain is a motif of about 60 residues that is frequently found in proteins involved in epigenetic regulation. Here, we determined the NMR solution structure of the zf-CW domain of the human zf-CW and PWWP domain containing